CorMedix (CRMD) Stock Price

CorMedix Price

NYSE AMEX·CLOSED
7.28
​
Market closed

Revenue has compounded at 170.8% per year over the past 12 years to 311.71 M USD. CorMedix's net margin stands at 52.3%, up from -9,207.7% several years earlier. Analysts set a median price target of 13.50 USD, implying 85.4% above the current price. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.

CorMedix stock price

Access this data via the Eulerpool API

CorMedix business model & stock analysis

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 40 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Frequently asked questions about CorMedix

Analysts currently set an average price target of 13.50 USD for the CorMedix stock (median: 13.50 USD), implying +85.4 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the CorMedix stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect CorMedix to generate revenue of 337.06 M USD and earnings per share of 0.42 USD.

Converted at the current exchange rate, the CorMedix share trades at 6.50 EUR (7.28 USD).

The CorMedix share (CRMD) is listed on 4 stock exchanges, including: NASDAQ (CRMD), Frankfurt (19KA.F), München (19KA.MU).

The expected revenue of CorMedix is 337.06 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of CorMedix is 39.00 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CorMedix is currently 17.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CorMedix stock.

The price-to-sales ratio (P/S) of CorMedix is currently 2.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the CorMedix stock.

The Eulerpool Quality Score for CorMedix is 7/10.

The ISIN of CorMedix is US21900C3088. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of CorMedix is A2PF3G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of CorMedix is CRMD. The ticker symbol is used to trade CorMedix shares on the stock exchange.

Fair ValueTerminal
6.04 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
1.63 M USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website cormedix.com
Currency
USD
Initial public offering
Mar 25, 2010
ISIN
US21900C3088
Cusip
21900C308
Market capitalization
573.59 M USDSmall Cap
52-Week Range
PEG
0.19
P/E ratio
P/Ee 2026
14.71
P/Ee 2027
128.47
P/Ee 2028
16.45
P/Ee 2029
7.43
P/Ee 2030
5.52
P/S
P/Se
2.03
EV/EBIT
3.82
P/B Ratio
1.42
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
29.57 %
Last updated Oct 8, 2026, 3:06 PM

CorMedix Peer Group

CorMedix Ticker

AMEX · CRMDFRANKFURT · 19KA.FMUNICH · 19KA.MUNASDAQ · CRMD

CorMedix FIGI

CRMD:US · BBG000Q4BQK0CRMD:UA · BBG000Q4BQN7CRMD:UC · BBG000Q4BR46CRMD:UN · BBG000Q4BRT9CRMD:UP · BBG000Q4BRZ2CRMD:UQ · BBG000Q4BSC5CRMD:UB · BBG000Q4BT06CRMD:UM · BBG000Q4BTR7CRMD:UX · BBG000Q4BVJ1CRMD:UD · BBG000Q4BXH9CRMD:UJ · BBG000Q4BYN0CRMD:UF · BBG000Q4BZ66

All fundamentals and in-depth analysis of CorMedix

Our stock analysis for CorMedix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CorMedix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.